Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
129
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
Enrolling by invitation Not applicable Interventional

ECHO for Diabetes and Multiple Chronic Conditions Study

NCT06451458
Conditions
Diabetes Mellitus, Chronic Disease
Interventions
ECHO program for DMMC, Usual care
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Santa Fe, New Mexico
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional

Early Identification and Action in CKD

NCT02208674
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Protocolized, pharmacist-delivered CKD Action Plan
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Danville, Pennsylvania
Conditions
Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions
Lifestyle Medicine Program, Medically Tailored Groceries
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Dyslipidemia, Renal Insufficiency
Interventions
ABT-335, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Gainesville, Florida • Miami, Florida • Minneapolis, Minnesota + 3 more
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

NCT05934292
Conditions
Hypercholesterolaemia
Interventions
Enlicitide Decanoate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Hallandale, Florida • Miami, Florida • Orlando, Florida + 1 more
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Denver, Colorado
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Conditions
Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
Interventions
Low-dose Colchicine at 0.5mg daily, Usual Care
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
Interventions
Med AAAction intervention
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Knoxville, Tennessee • Memphis, Tennessee
Conditions
Chronic Kidney Diseases, High Cholesterol
Interventions
Evolocumab, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Mineola, New York • New York, New York
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
TRF (Tocotrienol-rich-fraction), Placebo
Dietary Supplement
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan